Shares of Jazz Pharmaceuticals (JAZZ) have gained 8.9% over the past four weeks to close the last trading session at $127.74, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $175.83 indicates a potential upside of 37.7%.The average comprises 18 short-term price targets ranging from a low of $113 to a high of $230, with a standard deviation of $33.34. While the lowest estimate in ...

Have you assessed how the international operations of Jazz Pharmaceuticals (JAZZ) performed in the quarter ended September 2024? For this drugmaker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For inv ...

Jazz Pharmaceuticals (JAZZ) reported third-quarter 2024 adjusted earnings of $6.61 per share, which beat the Zacks Consensus Estimate of $5.47. Earnings rose 37% year over year.Total revenues rose 9% year over year to $1.05 billion. Sales of Xywav and Epidiolex drove this upside. The reported figure beat the Zacks Consensus Estimate of $1.04 billion.Shares of Jazz were up 2% in yesterday’s after-market trading session, likely due to the better-than-expected earnings.The stock fell 9.3% year to date compared ...

Product Performance - Jazz Pharmaceuticals reported approximately 13,625 patients taking Xywav as of Q3 2024, including about 10,075 with narcolepsy and 3,550 with idiopathic hypersomnia (IH) [88]. - The company achieved benefit coverage for Xywav in both narcolepsy and IH for approximately 90% of commercial lives in the U.S. [88]. - Xywav is recognized by the FDA as clinically superior to Xyrem due to its significantly lower sodium content, which is expected to reduce cardiovascular morbidity [88]. - Xywav received seven years of Orphan Drug Exclusivity from the FDA for narcolepsy, extending through January 2028 [88]. - Xywav has 92% lower sodium compared to high-sodium oxybates, with FDA recognizing seven years of ODE for Xywav in narcolepsy through July 21, 2027 [97]. - Xywav product sales increased by 17% to $388,466 thousand in Q3 2024 compared to $331,633 thousand in Q3 2023, and by 15% to $1,072,238 thousand for the nine months ended September 30, 2024, compared to $935,958 thousand in the same period in 2023 [102]. - Xyrem product sales decreased by 54% to $58,114 thousand in Q3 2024 compared to $125,110 thousand in Q3 2023, and by 60% to $184,526 thousand for the nine months ended September 30, 2024, compared to $463,009 thousand in the same period in 2023 [102]. - The company expects Xywav and Epidiolex/Epidyolex to remain its largest products, while also focusing on the commercialization of other existing and potential future products [131]. Pipeline and Development - Epidiolex was approved in the U.S. in June 2018 for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in patients aged two years and older [88]. - Rylaze was launched in the U.S. in July 2021 and is the only recombinant erwinia asparaginase product approved that maintains clinically meaningful asparaginase activity throughout treatment [89]. - The company focuses on expanding its pipeline in neuroscience and oncology therapeutic areas to address high unmet medical needs [84]. - Jazz Pharmaceuticals aims to enhance value through indication expansion and entry into global markets [84]. - Zanidatamab is under evaluation in multiple clinical trials for HER2-expressing cancers, with a BLA submission for second-line BTC completed in March 2024 and FDA Priority Review granted [91]. - The collaboration with Zymeworks for zanidatamab includes potential milestone payments of up to $1.4 billion, with total potential payments reaching $1.76 billion [91]. - JZP441, an orexin-2 receptor agonist, has achieved initial proof-of-concept in a Phase 1 trial, with plans for a Phase 1b trial in narcolepsy Type 1 patients in 2025 [92]. - The company has entered into a licensing agreement with Werewolf Therapeutics for JZP898, with potential milestone payments of up to $1.26 billion [92]. - The ongoing Phase 3 trial of Epidyolex in Japan did not meet its primary efficacy endpoint, but numeric improvements were observed in secondary endpoints [92]. - Zepzelca's ongoing Phase 3 trial in combination with Tecentriq showed positive top-line results in October 2024, indicating a statistically significant benefit in first-line maintenance treatment for extensive-stage SCLC [90]. - Rylaze received FDA approval for a new dosing schedule of 25/25/50 mg/m2 IM every Monday, Wednesday, and Friday in November 2022 [90]. Financial Performance - Product sales increased by 5% to $989,707 thousand in Q3 2024 compared to $938,398 thousand in Q3 2023, and by 1% to $2,795,953 thousand for the nine months ended September 30, 2024, compared to $2,769,604 thousand in the same period in 2023 [101]. - Royalties and contract revenues surged by 93% to $65,262 thousand in Q3 2024 from $33,742 thousand in Q3 2023, and totaled $184,824 thousand for the nine months ended September 30, 2024, compared to $52,665 thousand in the same period in 2023 [101]. - Total revenues increased by 9% to $1,054,969 thousand in Q3 2024 from $972,140 thousand in Q3 2023, and by 6% to $2,980,777 thousand for the nine months ended September 30, 2024, compared to $2,822,269 thousand in the same period in 2023 [102]. - Gross margin as a percentage of net product sales was 88.7% for both Q3 2024 and the nine months ended September 30, 2024, compared to 89.1% and 88.1% for the same periods in 2023 [106]. - The company expects total product sales to increase in 2024, driven by growth in Xywav, Epidiolex, and Rylaze, despite anticipated declines in Xyrem sales due to competition [104]. - The company anticipates royalties and contract revenues to increase in 2024, primarily due to higher royalty rates from net sales of high-sodium oxybate AG [105]. Expenses and Costs - Research and development expenses decreased by 15% to $199,919 thousand in Q3 2024 compared to $234,402 thousand in Q3 2023, while increasing by 2% to $643,500 thousand for the nine months ended September 30, 2024, compared to $633,050 thousand in the same period in 2023 [101]. - Selling, general and administrative expenses rose by 6% to $325,772 thousand in Q3 2024 from $308,310 thousand in Q3 2023, and increased by 7% to $1,016,007 thousand for the nine months ended September 30, 2024, compared to $947,071 thousand in the same period in 2023 [101]. - Clinical studies and outside services costs decreased by $31.7 million (22.6%) in Q3 2024 compared to Q3 2023, primarily due to lower costs related to zanidatamab and the absence of costs for JZP150 [110]. - Research and development expenses decreased by $34.5 million (14.7%) in the three months ended September 30, 2024, compared to the same period in 2023, but increased by $10.5 million (5.2%) in the nine months ended September 30, 2024 [110]. - Personnel expenses increased by $5.1 million (7.7%) in Q3 2024 compared to Q3 2023, driven by increased compensation costs [110]. Debt and Financing - The company had cash, cash equivalents, and investments of $2.6 billion as of September 30, 2024, with a long-term debt principal balance of $6.2 billion [116]. - A share repurchase program was authorized in July 2024 for up to $500 million, with $150 million spent to repurchase 1.4 million shares in Q3 2024 [119]. - The company completed a private placement of $1.0 billion principal amount of the 2030 Notes in September 2024 [127]. - An increase of $405.8 million in debt financing was due to net proceeds from the issuance of the 2030 Notes of $980.8 million, offset by the repayment of the 2024 Notes of $575.0 million [124]. - The 2030 Notes have an interest rate of 3.125% per year, payable semi-annually, and mature on September 15, 2030 [128]. - As of September 30, 2024, the interest rate and effective interest rate on the Tranche B-2 Dollar Term Loans were 7.10% and 8.27%, respectively [126]. - The company had an undrawn Revolving Credit Facility totaling $500.0 million as of September 30, 2024 [126]. Market and Competition - The company faces substantial competition from other companies, including those with larger sales organizations and more experience with diverse product portfolios [132]. - Xywav and Xyrem face competition from Avadel's Lumryz, which was launched in June 2023, leading to ongoing litigation regarding FDA's approval of Lumryz [97]. - In January 2023, an authorized generic version of high-sodium oxybate began impacting Xyrem and Xywav sales, with Hikma and Amneal launching their AG products in January and July 2023 respectively [98]. - Lupin received tentative approval for a generic version of Xywav on October 13, 2023, indicating increasing competition in the market [98]. - The commercial success of Epidiolex/Epidyolex is uncertain due to potential competition from generic products and non-FDA approved alternatives [98]. Regulatory and Legal Risks - The company is subject to significant ongoing regulatory obligations, which may lead to civil or criminal proceedings and additional expenses [134]. - Failure to comply with Medicaid Drug Rebate program obligations could result in penalties and adversely affect the company's financial condition [134]. - Ongoing legal proceedings and government investigations could result in significant monetary charges and distract from the company's operational strategy [99]. - The Inflation Reduction Act of 2022 may negatively impact the company's pricing strategies and revenue from sales of its products starting in 2026 [99]. - The company is subject to increasing pricing pressure and restrictions on reimbursement imposed by payors, which could adversely affect its financial condition [99]. Strategic Growth - The company intends to continue growing through acquisitions and in-licensing of differentiated products, but failure to do so could materially affect its business [98]. - The company is committed to developing life-changing medicines for patients with serious diseases, leveraging a robust pipeline of innovative therapeutics [84]. - The company is expanding its oncology pipeline through collaborations and licensing agreements, focusing on innovative therapies in hematology and precision oncology [91]. - To continue business growth, the company will need to commit substantial resources, potentially leading to future losses [134].

For the quarter ended September 2024, Jazz Pharmaceuticals (JAZZ) reported revenue of $1.05 billion, up 8.5% over the same period last year. EPS came in at $6.61, compared to $4.84 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.04 billion, representing a surprise of +1.75%. The company delivered an EPS surprise of +20.84%, with the consensus EPS estimate being $5.47.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings - ...

Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.61 per share, beating the Zacks Consensus Estimate of $5.47 per share. This compares to earnings of $4.84 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20.84%. A quarter ago, it was expected that this drugmaker would post earnings of $4.68 per share when it actually produced earnings of $5.30, delivering a surprise of 13.25%.Over the last four quarters, the c ...

Exhibit 99.1 Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results – 14% year-over-year revenue increase from combined key growth drivers: Xywav , Epidiolex and Rylaze – – 2024 total revenue guidance affirmed at $4.0 to $4.1 billion – – Zanidatamab 2L BTC PDUFA date of November 29, 2024 – – Plan to submit sNDA for Zepzelca in 1L ES-SCLC in 1H25 – ® ® ® ® DUBLIN, November 6, 2024 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2024 and updat ...

– 14% year-over-year revenue increase from combined key growth drivers:Xywav®, Epidiolex® and Rylaze® –– 2024 total revenue guidance affirmed at $4.0 to $4.1 billion –– Zanidatamab 2L BTC PDUFA date of November 29, 2024 –– Plan to submit sNDA for Zepzelca® in 1L ES-SCLC in 1H25 –DUBLIN, Nov. 6, 2024  /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2024 and updated guidance for 2024."Jazz once again delivered record revenues of more than $1.0 ...

Core Insights - The Ritz-Carlton, Naples is hosting its inaugural "NYE Black-Tie Gala" on New Year's Eve, featuring a luxurious five-course dinner and live jazz performances by Stella Cole, marking a significant addition to the resort's event offerings [2][3]. Event Details - The gala includes a 'Meet the Artist' reception, a five-course dinner curated by Executive Chef Satish Yerramilli, and a live performance by Stella Cole, culminating in a midnight countdown [4][5]. - Guests can enjoy premium bar selections and receive an autographed album of Stella Cole's debut release [5]. Ticket Pricing - Ticket options include Premiere Seating at $650 per person, Reserved Seating at $525 per person, and Large Table Reservations starting from $500 per person, all packages inclusive of taxes, gratuity, and valet parking [7]. Room Reservations - An exclusive "NYE Black-Tie Gala" package is available, which includes an overnight stay in a Coastal View Guestroom and two reserved seating-level tickets for the gala [8]. About The Ritz-Carlton, Naples - The Ritz-Carlton, Naples is a luxury resort featuring 474 guest rooms, a newly renovated Vanderbilt Tower, and various dining venues, recognized for its high standards and numerous accolades [10].

DUBLIN, Oct. 23, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 third quarter financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss 2024 third quarter financial results and provide a business and financial update.  Audio webcast/conference call: U.S. Dial-In Number: +1 800 715 9871Ireland Dial-In Number: +353 1800 9 ...